Specifically, EZH2 inhibition upregulates TAP1, restores MHC I expression on the tumor cell surface, and increases the presentation of antigenic peptides, making the tumor more likely to be recognized and targeted by the immune system (47). This evidence concerns the gene TAP1 and neoplasm.